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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of peripheral vascular catheter (PVC) dressings and securement devices on the incidence of PVC failure.
B A C K G R O U N D
Description of the condition
A peripheral venous catheter (PVC), often referred to as an intra-
venous cannula, is a flexible, hollow, plastic tube that is inserted
in a peripheral vein, most commonly the metacarpal vein of the
hand, and alternatively, either the cephalic or basilic vein of the
lower forearm (Tagalakis 2002; Dougherty 2008; O’Grady 2011).
It is typically used for short-term delivery of intravascular fluids
and medications. It is an essential element of modern medicine
and the most frequent invasive procedure performed in hospital,
with over 60% of all hospitalised patients requiring peripheral ve-
nous catheterisation (Wilson 2006). It has been conservatively re-
ported that patients have a PVC for 15% to 20% of the total time
they spend in an acute care hospital. (Zingg 2009). In the United
States, an estimated 330 million PVC are sold each year (Hadaway
2012).
The Infusion Nurses Society Standards recommend that PVCs be
re-sited when clinically indicated, and that decisions about when
to re-site should be based on an assessment of the patient’s PVC
site, including: skin and vein integrity, type of intravenous (IV)
therapy prescribed, the treatment setting, and patency of the PVC
and securing dressing or stabilisation device (INS 2011). PVCs
often fail before intravenous treatment is completed. Reported
failure rates, or unscheduled restarts, range from 33% to 69%
(Harwood 1992; Royer 2003; Smith 2006; Rickard 2010; Bolton
2010). PVCs fail for a wide range of reasons; the most commonly
identified causes of failure are partial dislodgement or accidental
removal, phlebitis (irritation or inflammation to the vein wall),
occlusion/infiltration (blockage/moving into surrounding tissue)
leakage and infection (Webster 2008; Bolton 2010;Rickard 2010).
1Devices and dressings to secure peripheral venous catheters to prevent complications (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dislodgement and accidental removal
Inadequate catheter stabilisation or securement can lead to poor
attachment of the PVC to the skin, allowing movement of the
catheter out of the vein, and resulting in partial or complete dis-
lodgement. PVC dislodgement rates have been reported to range
from 6% to as high as 20% of PVC insertions (Wood 1997; Royer
2003; Dillon 2008; Rickard 2010).
Phlebitis
Intravenous therapy can be disrupted by phlebitis, which is the
irritation and inflammation to a vein wall caused by the pres-
ence of an intravenous device (IVD) (Monreal 1999; Tagalakis
2002). Phlebitis can be categorised as chemical (caused by in-
fusates or medication), bacterial (caused by contamination of the
site, catheter, tubing or IV solution), or mechanical (caused by
the action of the catheter in the vessel) (Macklin 2003). An im-
properly secured IVD (intravascular device) allows micro-move-
ment of the catheter within the vein; this can irritate the vein
wall and lead to mechanical phlebitis (Sheppard 1999; Gallant
2006). Phlebitis is characterised by the presence of any combina-
tion of tenderness, pain, erythema (redness), oedema (swelling),
warmth, palpable cord (hard, thickened vein), or purulent (pus)
drainage ( Maki 1991; Tagalakis 2002; Gallant 2006). Phlebitis
rates range from 2.6% to 67.2% depending on the authors’ defi-
nition, study design, study population and the duration of follow-
up period (Catney 2001; White 2001; Karadeniz 2003; Malach
2006; Webster 2008; Rickard 2010; Rickard 2012).
Occlusion/infiltration and leakage
A poorly-stabilised PVC within a vein can damage the vessel wall,
instigating the release of thromboplastic substances and platelets
that promote blood clotting (Gabriel 2010). This process may
cause narrowing or occlusion of the catheterised vein, which then
forces the backflowandpotential leakage of IVfluids from the PVC
insertion site, or their infiltration into the surrounding tissues, and
restricts future venous access in the limb (Royer 2003; Gabriel
2010). Recent studies show PVC failure due to infiltration occur
in 12% to 36% of patients (Homer 1998; Catney 2001; Tagalakis
2002; Webster 2008; Rickard 2010).
Infection
Poor catheter stabilisation, particularly if it leads to unscheduled
PVC re-siting, may increase a patient’s risk of infection. In or-
der to be sited, a PVC must be inserted through the patient’s
skin, which normally acts as a protective barrier against bacteria
that might otherwise access the body. Consequently the catheter
may be contaminated during initial insertion or subsequent re-
sitings with a new PVC (Gabriel 2008). The most common cause
of catheter-related bloodstream infection (CRBSI) in short-term
catheters occurs when the skin has been broken. Micro-organisms
can cause local infection and may track along the surface of the
PVC to contaminate the catheter tip, and then the bloodstream
(Morris 2008; O’Grady 2011). Micro-motion while the PVC is
in place may also encourage microbial entry via the PVC wound
(Frey 2006). However, CRBSI occur less frequently in PVC than
in other intravascular devices (0.1% per PVC, 0.5 per 1000 PVC-
days) (Maki 2006).
Improper securement of a PVC to the skin allows the catheter to
move within the vein, which increases the incidence of PVC dis-
lodgement, mechanical phlebitis, infiltration, leakage and infec-
tion (Royer 2003; Bolton 2010; Gabriel 2010). This movement
results in PVC failure, an interruption to intravenous therapy and
the need to re-site the PVC. Repeated re-siting of PVC can lead
to venous access difficulties, including the need for more frequent
PVC re-sites or for a central venous catheter, and causing inter-
ruption to the delivery of IV therapy and a potential increase in
the duration of hospital stay and healthcare costs (Monreal 1999;
Tagalakis 2002; Dillon 2008).
Description of the intervention
The interventionof interest is thewounddressing(s) or securement
device(s) used for PVC stabilisation. Following clinical practice
protocols or clinician preference, two standard dressings are gen-
erally used to secure the PVC: either non sterile tape with gauze or
bandage; or a transparent dressing (Gabriel 2010; O’Grady 2011).
However, new products, such as antimicrobial-impregnated dress-
ings and sutureless (stitch-less) securement devices that are de-
signed to be used with the wound dressing to improve attachment
of the PVC to the skin, have recently become available.
Gauze/tape
A combination of tape with bandage or gauze has been widely
used to secure PVCs. This combination can range fromnon-sterile
tape and sterile gauze assembled by clinicians using products such
as Micropore® (3M) or Hypafix® (Smith & Nephew Healthcare
Ltd), to commercially-available dressings that combine a sterile
tape and gauze design, for example Primapore® (Smith&Nephew
Healthcare Ltd). However, gauze needs to be removed so that the
insertion site can be seen and this can potentially increase the
chance of catheter dislodgement or movement, resulting in com-
plications such as phlebitis, infiltration or occlusion (Campbell
1999). Furthermore, although gauze dressings are absorbant and
can prevent the pooling of moisture at the insertion site, when wet
they provide an ideal environment for the proliferation of infec-
tion-producing organisms (Campbell 1999; Gabriel 2010).
Transparent dressings
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Transparent dressings have been in use since the early 1980s and
offer clear visualisation of the PVC insertion site. The Opsite®
(Smith & Nephew Healthcare Ltd) and Tegaderm® (3M) ranges
of dressings are themost commonly used products (Webster 2011).
An early systematic review that compared gauze dressings to trans-
parent dressings for PVC securement found a significantly higher
infection risk with transparent dressings (Hoffmann 1992). This
was thought to be related to increased collection of moisture
(Hoffmann 1992). As a result of these studies, modern transpar-
ent dressings were developed that claim to have greater moisture
vapour permeability (MVP) (Wille 1993). A study comparing
standard Opsite and Opsite IV3000 for dressing central venous
catheters reportedMVPs of 800 g/m2 and 3000 g/m2, respectively
and no differences between the dressings for complications such
as moisture accumulation, lifting of dressing or durability (Wille
1993). Recently, new versions of these products, with additional
strongly-adhesive fabric borders, or additional sterile tapes to im-
prove securement, have become available.
Antimicrobial dressings
Antimicrobial dressings or impregnated discs have been developed
to aid prevention of CRBSIs, for example Biopatch® (Johnson
and Johnson) and Tegaderm CHG® (3M). The most common
source of infection for CRBSI is colonisation of the skin surround-
ing the insertion site, so antimicrobial dressings aim to reduce
colonisation, and thus decrease the incidence of CRBSI (Dainiels
2012). The Centers for Disease Control and Prevention recom-
mend the use of a chlorhexidine-impregnated sponge for tempo-
rary short-term catheters (typically used in intensive care units) if
the central line-associated bloodstream infection (CLABSI) rates,
are unacceptably high and not decreasing despite the implemen-
tation of basic preventative measures (i.e. education and training,
maximal sterile barrier precautions and >0.5% chlorhexidine in an
alcoholic solution for skin antisepsis) (O’Grady 2011). However,
there is no mention in the Guidelines of antimicrobial sponge/
dressing use in conjunction with peripheral catheters.
Sutureless securement devices
Sutureless securement devices have incorporated anchor points, or
clips, to hold the PVC in place more securely, for example Stat-
lock® (Bard Medical), Grip-Lok® (Zefon International) or Hub-
guard ® (Centurion Medical Products). It is reported that the
added attachment to the skin decreases catheter movement and
reduces complications such as phlebitis, dislodgement, infiltration
and vessel occlusion (Schears 2006). The Centers forDisease Con-
trol and Prevention has recommended use of sutureless secure-
ment devices to decrease the risk of infection (O’Grady 2011). The
Infusion Nurses Society advises that a stabilisation device should
be used in preference to tape or sutures when possible, to aid in
maintaining device integrity and minimisation of movement at
the catheter hub (INS 2011).
How the intervention might work
The aimof all PVCdressings and securement devices is tomaintain
a barrier to infection and to ensure that the device remains in the
vein.This review aims to examine the different PVC protection
and stabilisation methods; the impact they have on PVC dwell
time and stabilisation-related complications such as dislodgement,
phlebitis, occlusion/infiltration, leaking, and infection; and the
costs involved with the different products.
Identification of the most effective securement method may help
reduce stabilisation-related complications.
Why it is important to do this review
PVC insertion and IV therapy is a common procedure for hospi-
talised patients. Prevention of failure and unscheduled restarts of
PVC therapy is an important patient outcome: failure interrupts
prescribed therapy, and reinsertion can be distressing and painful.
A PVC that is not securely attached to the skin has the potential to
migrate externally and simply fall out, or cause complications such
as phlebitis and infiltration. An inadequately secured PVC also
increases the risk of CRBSI, as the pistoning action of the catheter
can allow migration of organisms along the catheter and into the
systemic circulation (Gabriel 2001;O’Grady 2011). These unnec-
essary complications can lead to delays in treatment and increases
in length of hospital stay (Bolton 2010). These factors have an
impact on health resources, as PVC replacement is time consum-
ing, requires skilled clinicians and disposable sterile equipment,
and CRBSIs cause significant increases in treatment costs (Bolton
2010; Gabriel 2010). Despite the many dressings and securement
devices available, the impact of different securement techniques
for increasing PVC dwell time is still unclear; there is a need to
provide guidance for clinicians by reviewing current studies sys-
tematically.
O B J E C T I V E S
To assess the effects of peripheral vascular catheter (PVC) dressings
and securement devices on the incidence of PVC failure.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing different dress-
ings or securement devices for the stabilisation of PVCs. Cross-
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over trials will be ineligible for inclusion, unless data for the first
treatment period can be obtained. Cluster randomised controlled
trials, where the cluster represents randomisation at the ward or
hospital level, will be excluded.
Types of participants
Any patients in any setting who require a PVC.
Types of interventions
Any trial comparing dressings or securement devices with another
dressing or securement device, for the protection or stabilisation
of a PVC. Dressings or securement devices that are made from any
type of product (e.g. polyurethane, gauze) will be eligible.
Types of outcome measures
Primary outcomes
• PVC failure where the PVC has been removed due to IV
complications, or has fallen out.
• Adverse events related to the different types of dressings and
securement devices.
Secondary outcomes
• Dislodgement and accidental removal.
• Time to catheter failure.
• Phlebitis, as identified by the trial investigator.
• Infiltration (the permeation of intravenous fluid or
medication into the surrounding tissue, resulting in swelling).
• Occlusion or inability to administer intravenous fluids.
• Catheter-related blood stream infections (CRBSI) with
laboratory confirmation of the catheter as the source of the
infection (O’Grady 2011).
• Suspected CRBSI, as identified by the trial investigator.
• Entry site local infection, as described by the trial
investigator.
• Skin damage, as described by the trial investigator.
• Cost (including cost or cost-effectiveness estimations, as
well as measurements of resource use such as number of dressing/
device changes, staff time).
• Patient satisfaction (using any validated instrument, e.g. a
visual analogue scale).
• Pain associated with dressing removal.
Search methods for identification of studies
Electronic searches
Wewill search the following electronic databases to identify reports
of relevant RCTs:
• The Cochrane Wounds Group Specialised Register;
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (latest issue);
• Ovid MEDLINE (1946 to present);
• Ovid EMBASE (1974 to present);
• EBSCO CINAHL (1982 to present).
We will use the following provisional search strategy in CEN-
TRAL:
#1 MeSH descriptor: [Catheterization, Peripheral] explode all
trees
#2 (peripheral venous catheter* or PVC):ti,ab,kw
#3 {or #1-#2}
#4 MeSH descriptor: [Occlusive Dressings] explode all trees
#5 (securement device* or Statlock or Hubguard):ti,ab,kw
#6 ((occlusive or gauze or tape or polyurethane or permeable or
nonpermeable or non-permeable or transparent or antimicrobial)
near/3 dressing*):ti,ab,kw
#7 (opsite or tegaderm or micropore or hypafix):ti,ab,kw
#8 {or #4-#7}
#9 {and #3, #8}
We will adapt this strategy to search Ovid MEDLINE, Ovid EM-
BASE and EBSCO CINAHL. We will combine the Ovid MED-
LINE search with the Cochrane Highly Sensitive Search Strategy
for identifying randomised trials in MEDLINE: sensitivity- and
precision-maximising version (2008 revision) (Lefebvre 2011).We
will combine the EMBASE search with the Ovid EMBASE filter
developed by the UK Cochrane Centre (Lefebvre 2011). We will
combine the CINAHL searches with the trial filters developed by
the Scottish IntercollegiateGuidelinesNetwork (SIGN 2014).We
will not restrict studies with respect to language, date of publica-
tion or study setting.
We will search the following clinical trials registries:
• ClinicalTrials,gov (http://www.clinicaltrials.gov/)
• WHO International Clinical Trials Registry Platform (
http://apps.who.int/trialsearch/Default.aspx)
• EU Clinical Trials Register (https://
www.clinicaltrialsregister.eu/
Searching other resources
We will search the reference lists of all relevant publications we
retrieve for other studies that have not been identified by the
search methods described above. We will also contact manufac-
turers of dressings and devices used to secure PVCs, such as Smith
& Nephew Healthcare Ltd, Bard and 3M, for information about
any on-going clinical trials.
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Data collection and analysis
Selection of studies
Two review authors (NM and JW) will review titles and abstracts
located by the search process independently. After obtaining full
copies of potentially relevant studies, the same two review authors
will assess their eligibility, independently, according to the inclu-
sion and exclusion criteria. A third review author’s (CR) opinion
will be sought if differences of opinion cannot be resolved by con-
sensus.
Data extraction and management
Two review authors (NM and JW) will perform data extraction of
all included RCTs independently, using a pre-designed checklist.
One review author (NM) will enter data into Review Manager
software (RevMan 2012), and a second review author (JW) will
check the data for accuracy. If information regarding any part of
the data is unclear, we will attempt to contact the study authors
of the original reports and ask them to provide further details. We
will include trials published as duplicate reports (parallel publica-
tions) once, using all associated trial reports to extract a maximal
amount of trial information, but ensuring that the trial data are
not duplicated in the review. We will extract the following infor-
mation:
• participant characteristics and exclusions;
• type of dressing or securement device;
• setting;
• study dates;
• unit of investigation (participant or catheter);
• interventions;
• length of follow-up;
• information about ethics approval, consent and any
declared conflicts of interest; and
• outcomes.
Assessment of risk of bias in included studies
Independently, two review authors (NM and JW) will assess the
included studies for risk of bias using the ’Risk of bias’ tool outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
This assessment of bias tool addresses seven specific domains (see
Appendix 1 for details), namely:
• sequence generation;
• allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessment;
• incomplete outcome data;
• selective outcome reporting;
• other possible problems that could put the study at risk of
bias.
Disagreements between the two review authors (NM and JW)will
be discussed and resolved by consensus, or referral to a third review
author (CR). The overall assessment of the risk of bias will be
presented using a ’Risk of bias’ summary figure, which will display
all judgements in a cross-tabulation of study by entry. This display
of internal validity will indicate the weight the reader can give to
the results of any particular study.
Measures of treatment effect
For dichotomous outcomes, we will calculate risk ratio (RR) plus
95% confidence intervals (CI). For continuous outcomes we will
calculate the mean difference (MD) plus 95% CI. We will analyse
any time-to-event data (e.g. time to development of phlebitis)
using hazard ratios and we will not analyse time-to-event data that
are incorrectly presented as continuous data.
Unit of analysis issues
Ideally a studywould be designedwith patient-level randomisation
and analysis, and only one device per participant (adjustment for
clustering not necessary in this case), however, we expect to find a
number of studies that report on multiple devices per participant,
randomised or analysed at device level, or both, and unadjusted
for clustering.
In such cases we will contact the study authors and attempt to
obtain: (1) patient-level data or results, (2) data or results for one
device per participant, or (3) device-level data, and then and per-
form multilevel regression to calculate the adjusted effect. The
adjusted results will then be combined in the meta-analysis with
those of patient-level trials (using the generic inverse method), and
sensitivity analyses will be performed (Higgins 2011). If we are
unsuccessful in obtaining the additional data required, then the
study will be excluded from the meta-analysis.
Cluster randomised controlled trials, where the cluster represents
randomisation at the ward or hospital level, will be excluded.
Dealing with missing data
The missing data for each study will be identified and an attempt
will bemade to contact the study authors to obtain the information
necessary for analysis. If the data cannot be obtained, an available-
case analysis will be performed on the available data. The potential
impact ofmissingdatawill be addressed in the discussion section of
the review. The impact of missing data on the study results will be
explored with a sensitivity analysis comparing the results from the
analyses of study completers with those from best-case and worst-
case scenarios. In the best-case scenario, all missing data from the
treatment group will be considered not to indicate PVC failure,
while those missing from the control group will be considered to
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indicate PVC failure. In the worst-case scenario missing data from
the treatment group will be considered to indicate PVC failure,
while those missing from the control group will be considered not
to indicate PVC failure.
Assessment of heterogeneity
Statistical heterogeneity will be tested for by using the Chi2 test,
with significance set at a P value of less than 0.10. In addition,
the degree of heterogeneity will be investigated by calculating the
I2 statistic (Deeks 2011). This describes the percentage of the
variability in effect estimates that is due to heterogeneity rather
than sampling error (chance). A rough guide to interpretation
is as follows: 0 to 40%: might not be important; 30% to 60%;
may represent moderate heterogeneity; 75% to 100%: represents
considerable heterogeneity (Deeks 2011).The importance of the
observed value of I2 depends on (1) the magnitude and direction
of effects, and (2) the strength of evidence for heterogeneity (e.g.
P value from the Chi2 test, or a confidence interval for I2) (Deeks
2011).
Assessment of reporting biases
If there are 10 or more studies included in our meta-analysis,
we will assess for reporting bias by using a funnel plot. If visual
inspection of the symmetry of the funnel plot shows that reporting
bias is present, we will include a statement in our results and a note
of caution in our discussion. Where possible, we will also access
trial protocols and compare the outcome measurements planned
with those reported.
Data synthesis
Review Manger will be used to perform the meta-analysis of in-
cluded studies (RevMan 2012). For dichotomous outcomes, we
will calculate risk ratio (RR) plus 95% confidence intervals (CI).
For continuous outcomes we will calculate the mean difference
(MD)plus 95%CI. If evidence of significant heterogeneity is iden-
tified (i.e. greater than 50%), potential causes will be explored, and
we will use a random-effects approach to the analysis, otherwise
we will use a fixed-effect method.
Subgroup analysis and investigation of heterogeneity
• Children (under 16 years of age) and adults.
• Continuous versus intermittent IV therapy.
• Additional bandaging versus dressing or securement device
alone.
Sensitivity analysis
We will perform sensitivity analysis to assess for the following:
• adequate concealment of allocation;
• size of studies (less than 100 patients);
• follow-up period of up to 48 hours;
• missing data - best/worst case scenarios.
’Summary of findings’ table
We will present the main results of the review in ’Summary of
findings’ tables. These tables present key information concerning
the quality of the evidence, the magnitude of the effects of the
interventions examined, and the sum of the available data for the
main outcomes (Schünemann 2011a). The ’Summary of findings’
tables also include an overall grading of the evidence related to
each of themain outcomes using theGRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) approach
(Schünemann 2011b). The GRADE approach defines the qual-
ity of a body of evidence with regard to the extent to which one
can be confident that an estimate of effect or association is close
to the quantity of specific interest. Quality of a body of evidence
involves consideration of within-trial risk of bias (methodological
quality), directness of evidence, heterogeneity, precision of effect
estimates and risk of publication bias (Schünemann 2011b). We
plan to present the following outcomes in the ’Summary of find-
ings’ tables:
• proportion of failed catheters;
• time to catheter failure;
• adverse events.
A C K N OW L E D G E M E N T S
The authors would like to acknowledge the contribution of the
peer referees: Anneke Andriessen, Kurinchi Gurusamy, Richard
Kirubakaran, RosWade and JanetWale, and copy editor Elizabeth
Royle.
6Devices and dressings to secure peripheral venous catheters to prevent complications (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
Additional references
Bolton 2010
Bolton D. Improving peripheral cannulation practice at
an NHS trust. British Journal of Nursing 2010;19(21):
1346–50.
Campbell 1999
Campbell H, Carrington M. Peripheral IV cannula
dressings: advantages and disadvantages. British Journal of
Nursing 1999;8(21):1420-2, 1424-7.
Catney 2001
Catney MR, Hillis S, Wakefield B, Simpson L, Domino L,
Keller S, et al. Relationship between peripheral intravenous
catheter dwell time and the development of phlebitis and
infiltration. Journal of Infusion Nursing 2001;24(5):332–41.
Dainiels 2012
Daniels KR, Frei CR. Antimicrobial-impregnated discs
for prevention of intravenous catheter-related infections.
American Journal of Infectious Diseases 2012;8(1):50–9.
Deeks 2011
Deeks JJ, Higgins JPT, Altmann DG, on behalf of
the Cochrane Statistical Methods Group and the
Cochrane Bias Methods Group (editors). Chapter 9:
Analysing data and undertaking meta-analysis. In:
Higgins JPT, Green S (editors). Cochrane Handbook
of Systematic Reviews of Interventions. Version 5.1.0
[updated March 2011]. The Cochrane Collaboration,
2011. Available from www.cochrane-handbook.org.
The Cochrane Collaboration, 2011. Available from
www.cochrane–handbook.org.
Dillon 2008
Dillon M.F, Curran J, Martos R, Walsh C, Walsh D, Zl-
Azawi, et al. Factors that affect longevity of intravenous
cannulas: a prospective study. Quarterly Journal of Medicine
2008;101(9):731–5.
Dougherty 2008
Dougherty L. Peripheral cannulation. Nursing Standard
2008;22(52):49-56; quiz 58.
Frey 2006
Frey AM, Schears GJ. Why are we stuck on tape and suture?
A review of catheter securement devices. Journal of Infusion
Nursing 2006;29(1):34–8.
Gabriel 2001
Gabriel J. PICC securement: minimising potential
complications. Nursing Standard 2001;15(43):42–4.
Gabriel 2008
Gabriel J. Infusion therapy part two: prevention and
management of complications. Nursing Standard 2008;22
(3):41–50.
Gabriel 2010
Gabriel J. Vascular access devices: securement and dressings.
Nursing Standard 2010;24(52):41–6.
Gallant 2006
Gallant P, Schultz AA. Evaluation of a visual infusion
phlebitis scale for determining appropriated discontinuation
of peripheral intravenous catheters. Journal of Infusion
Nursing 2006;29(6):338–45.
Hadaway 2012
Hadaway L. Short peripheral intravenous catheters and
infections. Journal of Infusion Nursing 2012;35(4):230–40.
Harwood 1992
Harwood IR, Greene LM, Kozakowski-Koch J, Rasor
J. New peripherally inserted midline catheter: a better
alternative for intravenous antibiotic therapy in patients
with Cystic Fibrosis. Pediatric Pulmonology 1992;12(4):
233–9.
Higgins 2011
Higgins JPT, Green S (editors). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
[updated March 2011]. The Cochrane Collaboration,
2011. Available from www.cochrane-handbook.org.
Hoffmann 1992
Hoffmann KK, Weber DJ, Samasa PS, Rutala WA.
Transparent polyurethane film as an intravenous catheter
dressing. JAMA 1992;267(15):2072–6.
Homer 1998
Homer LD, Holmes KR. Risks associated with 72- and 96-
hour peripheral intravenous catheter dwell times. Journal of
Intravenous Nursing 1998;21(5):301–5.
INS 2011
Infusion Nurses Society. Infusion nursing standards of
practice. Journal of Infusion Nursing 2011;34(1S):1–110.
Karadeniz 2003
Karadeniz G, Kutlu N, Tatlisumak E, Ozbakkaloglu B.
Nurses’ knowledge regarding patients with intravenous
catheters and phlebitis interventions. Journal of Vascular
Nursing 2003;11(2):44–7.
Lefebvre 2011
Lefebvre C, Manheimer E, Glanville J, on behalf of the
Cochrane Information Retrieval Methods Group. Chapter
6: Searching for studies. In: Higgins JPT, Green S
(editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 [updated March 2011].
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Macklin 2003
Macklin D. Phlebitis. American Journal of Nursing 2003;
103(2):55–60.
Maki 1991
Maki DG, Ringer M. Risk factors for infusion-related
phlebitis with small peripheral venous catheters. Annals of
Internal Medicine 1991;114(10):845–54.
Maki 2006
Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream
infection in adults with different intravascular devices: a
7Devices and dressings to secure peripheral venous catheters to prevent complications (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
systematic review of 200 published prospective studies.
Mayo Clinic Proceedings 2006;81(9):1159–71.
Malach 2006
Malach T, Jerassy Z, Rudensky B, Schlesinger Y, Broide
E, Olsha O, et al. Prospective surveillance of phlebitis
associated with peripheral intravenous catheters. American
Journal of Infection Control 2006;34(5):308–12.
Monreal 1999
Monreal M, Quilez F, Celestino R, Rodriguez S, Sopena
N, Neira C, Roca J. Infusion phlebitis in patients with
acute pneumonia: a prospective study. Chest 1999;115(6):
1576–80.
Morris 2008
Morris W, Tay MH. Strategies for preventing peripheral
intravenous cannula infection. British Journal of Nursing
2008;17(19):S14–21.
O’Grady 2011
O’Grady NP, Alexander M, Burns LA, Dellinger EP,
Garland J, Heard SO, et al. Guidelines for the prevention
of intravascular catheter-related infections, 2011. http://
www.cdc.gov/hicpac/BSI/BSI-guidelines-2011.html 2011.
RevMan 2012
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). 5.2. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2012.
Rickard 2010
Rickard CM,McCann D,Munnings J, McGrail M. Routine
resite of peripheral intravenous devices every 3 days did not
reduce complications compared with clinically indicated
resite: a randomised controlled trial. BMC Medicine 2010;8
(53):1–10.
Rickard 2012
Rickard CM, Webster J, Wallis MC, Marsh N, McGrail
M, French V, et al. Routine versus clinically indicated
replacement of peripheral intravenous catheters: a
randomised controlled equivalence trial. The Lancet 2012;
380:1066–74.
Royer 2003
Royer T. Improving short peripheral IV outcomes: a clinical
trial of two securement methods. Journal of the Association
for Vascular Access 2003;8(4):45–8.
Schears 2006
Schears GJ. Summary of product trials for 10,164 patients:
comparing an intravenous stabilizing device to tape. Journal
of Infusion Nursing 2006;29(4):225–31.
Schünemann 2011a
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE,
Glasziou P, Guyatt GH. Chapter 11: Presenting results
and ‘Summary of findings’ tables. In: Higgins JPT,
Green S (editors). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 [updated March
2011]. The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Schünemann 2011b
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT,
Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting
results and drawing conclusions. In: Higgins JPT, Green
S (editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 [updated March 2011].
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Sheppard 1999
Sheppard K, LeDesma M, Morris, NL, O’Connor K. A
prospective study of two intravenous catheter securement
techniques in skilled nursing facility. Journal of Intravenous
Nursing 1999;22(3):151.
SIGN 2014
Scottish Intercollegiate Guidelines Network (SIGN). Search
filters. http://www.sign.ac.uk/methodology/filters.html#
random (accessed 15 February 2014).
Smith 2006
Smith B. Peripheral intravenous catheter dwell times:
a comparison of 3 securement methods for the
implementation of a 96-hour scheduled change protocol.
Journal of Infusion Nursing 2006;29(1):14–7.
Tagalakis 2002
Tagalakis V, Kahn SR, Libman M, Blostein M. The
epidemiology of peripheral vein infusion thrombophlebitis:
a critical review. The American Journal of Medicine 2002;
113(2):146–51.
Webster 2008
Webster J, Clarke S, Paterson D, Hutton A, Van Dyk S, Gale
C, et al. Routine care of peripheral intravenous catheters
versus clinically indicated replacement: randomised
controlled trial. BMJ 2008;337:a339.
Webster 2011
Webster J, Gillies D, O’Riordan E, Sheriff KL, Rickard
CM. Gauze and tape and transparent polyurethane
dressings for central venous catheters. Cochrane Database
of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/
14651858.CD003827.pub2]
White 2001
White S. Peripheral intravenous therapy-related phlebitis
rates in an adult population. Journal of Intravenous Nursing
2001;24(1):19–24.
Wille 1993
Wille JC, Blussé van Oud Alblas A, Thewessen EAPM.
A comparison of two transparent film-type dressings in
central venous therapy. Journal of Hospital Infection 1993;
23:113–21.
Wilson 2006
Wilson J, Jenner EA. Infection Control in Clinical Practice.
3rd Edition. Bailliere Tindall Elsevier, 2006.
Wood 1997
Wood D. A comparative study of two securement techniques
for short peripheral intravenous catheters. Journal of
Intravenous Nursing 1997;20(6):280–5.
8Devices and dressings to secure peripheral venous catheters to prevent complications (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Zingg 2009
Zingg W, Pitter D. Peripheral venous catheters: an under-
evaluated problem. International Journal of Antimicrobial
Agents 2009;34(Suppl 4):S38–42.
∗ Indicates the major publication for the study
A P P E N D I C E S
Appendix 1. ’Risk of bias’ table judgement criteria
1. Was the allocation sequence generated adequately?
• Low risk of bias - adequate sequence generation is described in sufficient detail for example, using a computer random number
generator, random number tables, coin tossing or shuffling envelopes
• High risk of bias - non random component in sequence generation is described by the author. This description usually involves
a systematic non-random approach, for example, sequence generated by odd or even date of birth; by a rule based on date of
admission or on hospital or clinic record number.
• Unclear - Insufficient information about the sequence generation provided to make a judgement of risk of bias.
2. Was the allocation sequence adequately concealed?
• Low risk of bias - participants and investigators enrolling participants could not forsee allocation assignment because one of the
following methods was used for allocation concealment: central allocation, for example, via telephone, web-based and pharmacy-
controlled randomisation; sequentially-numbered drug containers of identical appearance; sequentially-numbered opaque, sealed
envelopes.
• High risk of bias - participants or investigators enrolling participants could possibly foresee assignments and thus introduce
selection bias, such as allocation based on: an open random allocation schedule; assignment without appropriate safeguards, for
example non-opaque envelopes or envelopes that were not sequentially-numbered; alternation of rotation; date of birth; case record
number; or any other unconcealed procedure.
• Unclear - Insufficient information about the concealment provided to make a judgement of risk of bias.
3. Blinding of participants and personnel - was knowledge about the allocation of interventions adequately
prevented during the study?
• Low risk of bias - either of the following: no blinding or incomplete blinding, but the review authors judge that the outcome is
not likely to be influenced by the lack of blinding; blinding of participants and the study personnel ensured, and unlikely that the
blinding could have been broken
• High risk of bias - either of the following: no blinding or incomplete blinding, and the outcome is likely to be influenced by
lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken and
the outcome is likely to be influenced by lack of blinding.
• Unclear - either of the following: insufficient information provided to permit judgement of risk of bias; or the study did not
address the outcome.
4. Blinding of outcome assessment - was knowledge of the allocated interventions adequately prevented during
the study?
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• Low risk of bias - either of the following: no blinding of outcome assessment but the review authors judge that the outcome
measurement is not likely to be influenced by the lack of blinding; blinding of the outcome assessment ensured, and unlikely that the
blinding could have been broken.
• High risk of bias - either of the following: no blinding of outcome assessment and the outcome measurement is likely to be
influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome
measurement is likely to be influenced by the lack of blinding.
• Unclear - either of the following: insufficient information provided to permit judgement of risk of bias; or the study did not
address this outcome.
5. Were incomplete outcome data adequately addressed?
• Low risk of bias - any one of the following: no missing outcome data; reasons for missing outcome data are unlikely to be related
to true outcome (for survival data, censoring is unlikely to be introducing bias); missing outcome data balanced in numbers across
intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing
outcomes compared with observed event risk is not enough to have a clinically relevant impact on the intervention effect estimate; for
continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes is
not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.
• High risk of bias - any one of the following: reason for missing outcome data is likely to be related to true outcome, with either
imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of
missing outcomes compared with observed event risk is enough to induce clinically relevant bias in intervention effect estimate; for
continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes is
enough to induce clinically relevant bias in observed effect size; ‘as-treated’ analysis done with substantial departure of the
intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.
• Unclear - either of the following: insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias
(e.g. number randomised not stated, no reasons for missing data provided); the study did not address this outcome.
6. Are reports of the study free of suggestion of selective outcome reporting?
• Low risk of bias - either of the following: the study protocol is available and all of the study’s pre-specified (primary and
secondary) outcomes that are of interest in the review have been reported in the pre-specified way; the study protocol is not available
but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this
nature may be uncommon).
• High risk of bias - any one of the following: not all of the study’s pre-specified primary outcomes have been reported; one or
more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-
specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided,
such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be
entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for
such a study.
• Unclear - insufficient information provided to permit judgement of risk bias.
7. Other sources of potential bias
• Low risk of bias - the study appears to be free of other sources of bias.
• High risk of bias - there is at least one important risk of bias, for example the study: had a potential source of bias related to the
specific study design used; or had extreme baseline imbalance; or has been claimed to have been fraudulent; or had some other
problem.
• Unclear - there may be a risk of bias, but there is either: insufficient information to assess whether an important risk of bias
exists; or insufficient rationale or evidence that an identified problem will introduce bias.
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Appendix 2. Glossary
Colonisation: the presence of bacteria or other micro-organisms in a specific body part or a device in the body.
Dwell time: number of hours/days that a device remains in a patient.
Erythema: redness or inflammation of the skin.
Intravascular device: a catheter or device that is placed within a vessel (vein or artery) and used for intravascular access
Intravascular fluids: liquid that is delivered intravascularly, usually from a fluid bag, via a line or administration set and through an
intravascular device.
Peripheral venous catheter (PVC): a flexible, hollow, plastic tube that is inserted into a peripheral vein
Phlebitis: irritation to a vein wall caused by the presence of an intravascular device
Skin integrity: a description of a patient’s skin, whether it is intact or not
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